Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/targeting-the-immune-system-in-breast-cancer-hype-or-hope-tils-and-en61AFuO2O
References (54)
-
R. Salgado, R. Salgado, C. Denkert, S. Demaria, N. Sirtaine, F. Klauschen, G. Pruneri, S. Wienert, G. Eynden, F. Baehner, F. Penault-Llorca, E. Perez, E. Thompson, W. Symmans, A. Richardson, J. Brock, C. Criscitiello, H. Bailey, M. Ignatiadis, G. Floris, J. Sparano, Z. Kos, T. Nielsen, D. Rimm, K. Allison, J. Reis-Filho, S. Loibl, C. Sotiriou, G. Viale, S. Badve, S. Adams, K. Willard-Gallo, S. Loi (2015)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.Annals of oncology : official journal of the European Society for Medical Oncology, 26 2
-
Nathan West, K. Milne, P. Truong, N. Macpherson, B. Nelson, P. Watson (2011)
Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancerBreast Cancer Research : BCR, 13
-
L. Emens (2012)
Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockadeExpert Review of Anticancer Therapy, 12
-
H. Soliman (2010)
Developing an effective breast cancer vaccine.Cancer control : journal of the Moffitt Cancer Center, 17 3
-
G. Freeman, A. Long, Yoshiko Iwai, K. Bourque, T. Chernova, H. Nishimura, L. Fitz, Nelly Malenkovich, Taku Okazaki, M. Byrne, H. Horton, L. Fouser, L. Carter, V. Ling, M. Bowman, B. Carreno, M. Collins, C. Wood, T. Honjo (2000)
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte ActivationThe Journal of Experimental Medicine, 192
-
Yasmin Issa-Nummer, S. Darb-Esfahani, S. Loibl, G. Kunz, V. Nekljudova, I. Schrader, B. Sinn, H. Ulmer, R. Kronenwett, M. Just, T. Kühn, K. Diebold, M. Untch, F. Holms, J. Blohmer, J. Habeck, M. Dietel, F. Overkamp, P. Krabisch, G. Minckwitz, C. Denkert (2013)
Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer – A Substudy of the Neoadjuvant GeparQuinto TrialPLoS ONE, 8
-
S. Loi, N. Sirtaine, F. Piette, R. Salgado, G. Viale, F. Eenoo, G. Rouas, P. Francis, J. Crown, E. Hitre, E. Azambuja, E. Quinaux, A. Leo, S. Michiels, M. Piccart, C. Sotiriou (2013)
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 7
-
C. Denkert, G. Minckwitz, J. Brase, B. Sinn, S. Gade, R. Kronenwett, B. Pfitzner, C. Salat, S. Loi, W. Schmitt, C. Schem, K. Fisch, S. Darb-Esfahani, K. Mehta, C. Sotiriou, S. Wienert, P. Klare, F. André, F. Klauschen, J. Blohmer, K. Krappmann, Marcus Schmidt, H. Tesch, S. Kümmel, P. Sinn, C. Jackisch, M. Dietel, T. Reimer, M. Untch, S. Loibl (2015)
Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 9
-
E. Holmes (1985)
Immunology of Tumor Infiltrating LymphocytesAnnals of Surgery, 201
-
DT Le, JN Uram, H Wang, BR Bartlett, H Kemberling, AD Eyring (2015)
PD-1 blockade in tumors with mismatch-repair deficiencyN Engl J Med, 372
-
G. Basu, A. Ghazalpour, Z. Gatalica, K. Anderson, A. McCullough, D. Spetzer, B. Pockaj (2014)
Expression of novel immunotherapeutic targets in triple-negative breast cancer.Journal of Clinical Oncology, 32
-
E. Mittendorf, A. Philips, F. Meric-Bernstam, N. Qiao, Yun Wu, S. Harrington, X. Su, Ying Wang, A. González-Angulo, A. Akcakanat, A. Chawla, M. Curran, P. Hwu, P. Sharma, J. Litton, J. Molldrem, G. Alatrash (2014)
PD-L1 Expression in Triple-Negative Breast CancerCancer Immunology Research, 2
-
L. Coussens, J. Pollard (2011)
Leukocytes in mammary development and cancer.Cold Spring Harbor perspectives in biology, 3 3
-
M. Disis, V. Goodell, K. Schiffman, K. Knutson (2004)
Humoral Epitope-Spreading Following Immunization with a HER-2/neu Peptide Based Vaccine in Cancer PatientsJournal of Clinical Immunology, 24
-
E. Garon, L. Gandhi, N. Rizvi, R. Hui, A. Balmanoukian, A. Patnaik, J. Eder, G. Blumenshein, C. Aggarwal, J. Soria, M. Ahn, M. Gubens, S. Ramalingam, Elizabeth Johnson, H. Arkenau, G. Lubiniecki, Jin Zhang, R. Rutledge, K. Emancipator, N. Leighl (2014)
LBA43ANTITUMOR ACTIVITY OF PEMBROLIZUMAB (PEMBRO; MK-3475) AND CORRELATION WITH PROGRAMMED DEATH LIGAND 1 (PD-L1) EXPRESSION IN A POOLED ANALYSIS OF PATIENTS (PTS) WITH ADVANCED NON–SMALL CELL LUNG CARCINOMA (NSCLC)Annals of Oncology, 25
-
G. Minckwitz, S. Harder, S. Hövelmann, E. Jäger, S. Al-Batran, S. Loibl, A. Atmaca, Christian Cimpoiasu, A. Neumann, A. Abera, A. Knuth, M. Kaufmann, D. Jäger, A. Maurer, W. Wels (2005)
Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomasBreast Cancer Research, 7
-
M. Ono, H. Tsuda, C. Shimizu, Sohei Yamamoto, T. Shibata, H. Yamamoto, T. Hirata, K. Yonemori, M. Ando, K. Tamura, N. Katsumata, T. Kinoshita, Y. Takiguchi, H. Tanzawa, Y. Fujiwara (2012)
Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancerBreast Cancer Research and Treatment, 132
-
C. Denkert, S. Loibl, A. Noske, M. Roller, B. Müller, M. Komor, J. Budczies, S. Darb-Esfahani, R. Kronenwett, C. Hanusch, C. Törne, W. Weichert, K. Engels, C. Solbach, I. Schrader, M. Dietel, G. Minckwitz (2010)
Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 1
-
E. Mittendorf, G. Clifton, J. Holmes, E. Schneble, D. Echo, S. Ponniah, G. Peoples (2014)
Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients.Annals of oncology : official journal of the European Society for Medical Oncology, 25 9
-
J. Gribben, D. Ryan, R. Boyajian, R. Urban, M. Hedley, K. Beach, Patrick Nealon, U. Matulonis, S. Campos, T. Gilligan, P. Richardson, B. Marshall, D. Neuberg, L. Nadler (2005)
Unexpected Association between Induction of Immunity to the Universal Tumor Antigen CYP1B1 and Response to Next TherapyClinical Cancer Research, 11
-
S. Mahmoud, S. Mahmoud, Andrew Lee, E. Paish, R. Macmillan, I. Ellis, I. Ellis, A. Green (2012)
The prognostic significance of B lymphocytes in invasive carcinoma of the breastBreast Cancer Research and Treatment, 132
-
J. Taube, R. Anders, Geoffrey Young, Haiying Xu, Rajni Sharma, T. McMiller, Shuming Chen, A. Klein, D. Pardoll, S. Topalian, Lieping Chen (2012)
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune EscapeScience Translational Medicine, 4
-
J. Murray, Michael Gillogly, D. Przepiorka, H. Brewer, N. Ibrahim, D. Booser, G. Hortobagyi, A. Kudelka, K. Grabstein, M. Cheever, C. Ioannides (2002)
Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, 8 11
-
D. DeNardo, L. Coussens (2007)
Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progressionBreast cancer research : BCR, 9
-
John Park, M. Melisko, L. Esserman, L. Jones, Jami Wollan, R. Sims (2007)
Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 24
-
A. Cimino-Mathews, J. Foote, L. Emens (2015)
Immune targeting in breast cancer.Oncology, 29 5
-
Gang Chen, Richa Gupta, S. Petrik, M. Laiko, J. Leatherman, J. Asquith, M. Daphtary, E. Garrett-Mayer, N. Davidson, K. Hirt, M. Berg, J. Uram, T. Dauses, J. Fetting, E. Duus, S. Atay-Rosenthal, X. Ye, A. Wolff, V. Stearns, E. Jaffee, L. Emens (2014)
A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF–Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast CancerCancer Immunology Research, 2
-
D. DeNardo, L. Coussens (2007)
Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression -
K. Schalper, V. Velcheti, Daniel Carvajal, Hallie Wimberly, Jason Brown, L. Pusztai, D. Rimm (2014)
In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast CarcinomasClinical Cancer Research, 20
-
E. Perez, K. Ballman, S. Anderson, E. Thompson, S. Badve, H. Bailey, Fl Baehner (2015)
Abstract S1-06: Stromal tumor-infiltrating lymphocytes(S-TILs): In the alliance N9831 trial S-TILs are associated with chemotherapy benefit but not associated with trastuzumab benefitCancer Research, 75
-
E. Garon, N. Rizvi, R. Hui, N. Leighl, A. Balmanoukian, J. Eder, A. Patnaik, C. Aggarwal, M. Gubens, L. Horn, E. Carcereny, M. Ahn, E. Felip, Jong-Seok Lee, M. Hellmann, O. Hamid, J. Goldman, J. Soria, M. Dolled-Filhart, R. Rutledge, Jin Zhang, J. Lunceford, Reshma Rangwala, G. Lubiniecki, C. Roach, K. Emancipator, L. Gandhi (2015)
Pembrolizumab for the treatment of non-small-cell lung cancer.The New England journal of medicine, 372 21
-
M. Dieci, M. Dieci, C. Criscitiello, A. Goubar, G. Viale, P. Conte, V. Guarneri, G. Ficarra, M. Mathieu, S. Delaloge, G. Curigliano, F. André (2014)
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study.Annals of oncology : official journal of the European Society for Medical Oncology, 25 3
-
R. Nanda, L. Chow, E. Dees, R. Berger, Shilpa Gupta, R. Geva, L. Pusztai, M. Dolled-Filhart, K. Emancipator, Edward Gonzalez, J. Houp, K. Pathiraja, V. Karantza, R. Iannone, C. Gause, Johnathan Cheng, L. Buisseret (2015)
Abstract S1-09: A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancerCancer Research, 75
-
M. Diego, Azevedo Lucas, de Tais, F. Milena, Peria Fernanda, Bisson Gabriela (2014)
P-0205CYTOKINES, DEPRESSION AND ANXIETY IN COLORECTAL CANCER PATIENTS IN DIFFERENT STAGES OF THE ANTITUMOR THERAPYAnnals of Oncology, 25
-
S. Adams, R. Gray, S. Demaria, L. Goldstein, E. Perez, L. Shulman, S. Martino, Molin Wang, V. Jones, T. Saphner, A. Wolff, W. Wood, N. Davidson, G. Sledge, J. Sparano, S. Badve (2014)
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 27
-
A. Seo, H. Lee, E. Kim, H. Kim, M. Jang, H. Lee, Y. Kim, Jae Kim, S. Park (2013)
Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancerBritish Journal of Cancer, 109
-
C. Constantinou, I. Fentiman (2013)
Inflammation and breast cancerBreast cancer management, 2
-
S. Demaria, M. Volm, R. Shapiro, H. Yee, R. Oratz, S. Formenti, F. Muggia, W. Symmans (2001)
Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research, 7 10
-
M. Disis, D. Wallace, T. Gooley, Y. Dang, M. Slota, Hailing Lu, A. Coveler, J. Childs, D. Higgins, P. Fintak, C. Rosa, K. Tietje, J. Link, J. Waisman, L. Salazar (2009)
Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 28
-
S. Hato, Andrea Khong, I. Vries, W. Lesterhuis (2014)
Molecular Pathways: The Immunogenic Effects of Platinum-Based ChemotherapeuticsClinical Cancer Research, 20
-
L. Emens, F. Braiteh, P. Cassier, J. Delord, J. Eder, M. Fassò, Yuanyuan Xiao, Yan Wang, L. Molinero, Daniel Chen, I. Krop (2015)
Abstract 2859: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC)Cancer Research, 75
-
S. Loi, S. Loi, S. Michiels, S. Michiels, R. Salgado, N. Sirtaine, V. Jose, D. Fumagalli, P. Kellokumpu-Lehtinen, P. Bono, V. Kataja, C. Desmedt, M. Piccart, S. Loibl, C. Denkert, M. Smyth, H. Joensuu, C. Sotiriou (2014)
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.Annals of oncology : official journal of the European Society for Medical Oncology, 25 8
-
Daniel Jc, Ritzmann Se, Levin Wc (1968)
Lymphocytes: morphological, developmental, and functional characteristics in health, disease, and experimental study--an analytical review.Texas reports on biology and medicine, 26 1
-
D. Pardoll (2012)
The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 12
-
G. Curigliano, C. Criscitiello, A. Esposito, L. Fumagalli, L. Gelao, M. Locatelli, I. Minchella, A. Goldhirsch (2013)
Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium.Breast, 22 Suppl 2
-
G. Dunn, A. Bruce, H. Ikeda, L. Old, R. Schreiber (2002)
Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 3
-
B. Kreike, Marieke Kouwenhove, H. Horlings, B. Weigelt, H. Peterse, H. Bartelink, M. Vijver (2007)
Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomasBreast cancer research : BCR, 9
-
R. Salgado, C. Denkert, C. Campbell, P. Savas, P. Nuciforo, C. Aura, E. Azambuja, H. Eidtmann, C. Ellis, J. Baselga, M. Piccart-Gebhart, S. Michiels, I. Bradbury, C. Sotiriou, S. Loi (2015)
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.JAMA oncology, 1 4
-
E. Mittendorf, A. Philips, F. Meric-Bernstam, N. Qiao, Yun Wu, S. Harrington, X. Su, Ying Wang, A. González-Angulo, A. Akcakanat, A. Chawla, M. Curran, P. Hwu, P. Sharma, J. Litton, J. Molldrem, G. Alatrash (2014)
PD-L 1 Expression in Triple-Negative Breast Cancer -
Y. Mao, Q. Qu, Yuzi Zhang, Junjun Liu, Xiao-song Chen, K. Shen (2014)
The Value of Tumor Infiltrating Lymphocytes (TILs) for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer: A Systematic Review and Meta-AnalysisPLoS ONE, 9
-
Z. Gatalica, C. Snyder, Todd Maney, A. Ghazalpour, D. Holterman, N. Xiao, P. Overberg, I. Rose, G. Basu, S. Vranić, H. Lynch, D. Hoff, O. Hamid (2014)
Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer TypeCancer Epidemiology, Biomarkers & Prevention, 23
-
Brenda Ernst, K. Anderson (2015)
Immunotherapy for the Treatment of Breast CancerCurrent Oncology Reports, 17
-
T. Tanaka, E. Cooper, C. Anderson (1970)
Lymphocyte infiltration in bladder carcinoma.Revue europeenne d'etudes cliniques et biologiques. European journal of clinical and biological research, 15 10
-
T. Aparicio (2015)
PD-1 blockade in tumors with mismatch-repair deficiencyCôlon & Rectum, 9
- Publisher
- Springer Journals
- Copyright
- Copyright © 2015 by Springer Science+Business Media New York
- Subject
- Medicine & Public Health; Oncology; Internal Medicine; Surgical Oncology
- ISSN
- 1943-4588
- eISSN
- 1943-4596
- DOI
- 10.1007/s12609-015-0193-0
- Publisher site
- See Article on Publisher Site
Abstract
Immunotherapy in breast cancer is currently an appealing topic of research. With the understanding of the complex mechanisms of the immune system and the interaction between this and the tumor, new potential targets have emerged. It is also becoming clear that some breast cancer subtypes, such as triple-negative and HER2+ breast cancer, can be considered immunologic tumors. Therefore, new therapeutic strategies can be investigated. In this review, we offer an overview on PD-1/PD-L1 and CTLA4 checkpoint inhibitors, the most studied immune target therapies in triple-negative breast cancer (TNBC) and HER2+ breast cancer. We will also focus our attention of tumor-infiltrating lymphocytes (TILs).
Journal
Current Breast Cancer Reports – Springer Journals
Published: Sep 30, 2015